Scientific Symposium Opening session CTOS (1 pm to 5 pm)

Slides:

Advertisements

Similar presentations

1 RIDER and MIRC R… I… D… E… R… Medical Imaging Resource Center.

Advertisements

A Phase II Trial of Perifosine in Patients with Chemo-Insensitive Sarcomas Dejka M. Steinert, MD.

Clinical Trials What Are They and When Are They Right For You? Maura N. Dickler Assistant Attending Physician Breast Cancer Medicine Service Memorial Sloan-Kettering.

A Proposal for BMS (Dasatinib) in GIST Jon Trent, MD, PhD Assistant Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson.

George D. Demetri Graduated: Stanford Medical School Residency: Univ. of Washington Hospitals Internal Medicine Fellowship: Dana Farber Cancer Institute,

SARC Business Meeting November Trial Update SARC 001 Gleevec –Closed to accrual –Outstanding data –Requests SARC 002 STS/gem-txt –Closed to accrual.

SARC023 Phase I/II trial of ganetespib, an heat shock protein 90 inhibitor in combination with the mTOR inhibitor sirolimus for patients with unresectable.

A blanket protocol to study oral regorafenib in patients with refractory liposarcoma, osteogenic sarcoma, and Ewing/Ewing-like sarcoma Coordinating Investigator:

BRAF inhibitors in HCL Thorsten Zenz, MD

Update on GIST Research

November 2006 Phase II Study of Dasatinib in Advanced Sarcoma SARC 009 Coordinating site: University of Michigan.

Clinical Trials – An Academic Perspective Mohammed Milhem, MD University of Iowa.

A PHASE II TRIAL OF PERIFOSINE IN PATIENTS WITH CHEMO-INSENSITIVE SARCOMAS A SARCOMA ALLIANCE FOR RESEARCH THROUGH COLLABORATION (SARC) STUDY Study Update.

Maki RG, Wathen JK, Patel SR, Priebat DA,

SARC015: Phase II study of R1507 in wild-type GIST Margaret von Mehren, Fox Chase Cancer Center Katie Janeway, Dana Farber Cancer Institute.

SARC 005: Adjuvant treatment of high risk uterine LMS with gemcitabine/docetaxel followed by doxorubicin: a phase II multi-center trial PI: Martee.

G. Scott Gazelle, MD, MPH, PhD Director, Partners Radiology Partners Radiology Research Retreat February 26, 2010.

What would you recommend as first line therapy for a 68 y/o woman with advanced pancreatic cancer and limited metastatic disease with ECOG-1? Gemcitabine.

Paris- RP Reims Rennes Tours Marseille Montpellier Lyon Nice Lille Strasbourg Bordeaux Dijon Besançon Nantes Toulouse Poitiers Angers Nancy Caen Rouen.

SARC studies: an overview

SARC Initially the North American Consortium of CTOS 501.c.3 organization Incorporated November 2003.

Steady-State Plasma Imatinib Levels in 142 GIST Patients Distribution, Dose, Dose Escalation, and Response Laura K Nolden 1, Linyee Shum 2, Amaury Dumont.

A Phase II Trial of Perifosine in Patients with Chemo-Insensitive Sarcomas Study Update – November 2008 Dejka Araujo, MD MD Anderson Cancer Center, Houston,

Chair:Dr. Vivien Bramwell NATIONAL CANCER INSTITUTE OF CANADA CLINICAL TRIALS GROUP Sarcoma Committee CANADIAN SARCOMA GROUP.

CTOS IS TEN YEARS OLD SARC IS TWO YEARS OLD Happy Birthday, CTOS, SARC.

Anatomic and Functional Imaging Evaluation of a Clinical Trial of an IGFR Antibody in Patients (PTS) with Ewing Sarcoma (ES) Vadim Koshkin; Vanessa Bolejack;

SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Unresectable Malignant Peripheral Nerve Sheath Tumors.

SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.

Accounting for Patient Heterogeneity 1) Hierarchical Bayesian Approaches 2) ANOVA – Based Approaches Thall, et al., Statistics in Medicine 2003.

Phase II Study of Dasatinib in Advanced Sarcomas SARC009 Sarcoma PI: Scott Schuetze GIST PI: Jon Trent Registration and eCRF: CRAB, Seattle Drug Supply:

Copyright © 2011 Research To Practice. All rights reserved. Faculty National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current.

Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results.

Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Malignant Peripheral Nerve Sheath Tumors Brigitte Widemann,

Phase 2 study of the mTOR inhibitor RAD001 (everolimus) in combination with bevacizumab (avastin) in patients with sporadic and neurofibromatosis type.

A Randomized, Double-Blinded, Placebo- Controlled, Multi-Institutional, Cross-Over Phase II.5 Study of Saracatinib, a Selective Src Kinase Inhibitor, in.

Phase II Study of the BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia ( NCT ) Martin S. Tallman, M.D.

SARC 005: Adjuvant treatment of high risk uterine LMS with gemcitabine/docetaxel followed by doxorubicin: a phase II multi- center trial PI: Martee L.

The 2005 Chawla-Rosenfeld Symposium on Developmental Therapeutics for Sarcoma Introduction George D. Demetri, MD Dana-Farber Cancer Institute Harvard Medical.

MEASURING CLINICAL EFFICACY IN PHASE II TRIALS Response: Karnofsky, WHO, RECIST Event rate: progression free/survival Time to event: progression/survival.

INTERGROUP COALITION AGAINST SARCOMAS (ICAS) SCIENTIFIC STEERING COMMITTEE: EC Borden, G Demetri, M von Mehren, K Albritton, P Pisters BIOSTATISTICS: C.

Phase II Study of Dasatinib (BMS ) in Advanced Sarcomas and Chordoma Coordinating Center: U Michigan.

Neoadjuvant Imatinib in DFSP SARC 004 University of Michigan coordinating center.

12 th Annual CTOS Meeting 2006 AP23573 Induced Long-term Stability in 2 Patients with Desmoplastic Small Round Cell Tumor (#561) Scott Schuetze, Warren.

The President’s Cancer Panel 2004/2005 Series Translating Research to Reduce the Burden of Cancer Margaret L. Kripke, Ph.D. January 25, 2005.

Adjuvant therapy: LMS High activity of gemcitabine/docetaxel in advance disease suggests potential role as adjuvant therapy Adjuvant phase II study of.

ENDOMETRIAL CARCINOMA UPDATES Dr Marco Matos Gold Coast Cancer Care, Gold Coast University Hospital and Pacific Private Oncology Group.

What you need to know about Prostate Cancer. Brian McGarry’s Story 1/30/2014 To: DCS Faculty From: Brian McGarry Patty and I received news in the last.

(aka---how to know where to look and who to call).

Pediatric GIST: KIT inhibitors & IGF1R-directed antibodies January 22, 2009 Katherine Janeway, MD.

ACOSOG Sarcoma Committee Chair: Peter W.T. Pisters, MD Vice Chairs: Edward Cheng, MD (Orthopedic Oncology) Robert Maki, MD, PhD (Medical Oncology) Brian.

Precision Medicine: The Potential for Identifying Personalized Therapies for Patients with Gastro-Esophageal Cancer.

SurVaxM Cancer Immunotherapy

How to Find and Participate in a GIST clinical trial

When Executive Education is a Process, Not a Program

ASPEN: Prolonged PFS With Sunitinib vs Everolimus in Nonclear-Cell RCC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 -

The POSITIVE study A large international research effort coordinated by International Breast Cancer Study Group (IBCSG) worldwide ALLIANCE for Clinical.

State of the Art in BRCA-Mutated Ovarian Cancer

Which Adjuvant Systemic Treatments Would Medical Oncologists Wish to Receive If They Had Colon Cancer? A Survey of 150 Physicians N Love, MD1; NJ Meropol,

GSF: Groupe Sarcome Français

ICAS: CTOS 2005 Review of Studies

Investigación en Sarcomas GEIS Spanish Sarcoma Research Group

Bergh J et al. SABCS 2009;Abstract 23.

ACOSOG Clinical Trials

Current RTOG Soft Tissue Sarcoma Trials

Physical and Psychological Sequelae of Breast Cancer in Men

How to Find and Participate in a GIST clinical trial

Dejka Araujo, MD MD Anderson Cancer Center, Houston, TX

NRG Main Members Lead Academic Performance Sites (LAPS) 30

NRG Oncology Biospecimen Bank Report NRG Semiannual meeting

Clinical Trials and Black History-Shaping a Brighter Future

Presentation transcript:

Scientific Symposium Opening session CTOS (1 pm to 5 pm) CTOS reception (5pm to 6pm) Dinner/Consensus Discussion (6pm to 9 pm) Panel George Demetri, MD Scott Schuetze, MD, PhD Laurence Baker, DO (moderator)

Gleevec G Vs. Gem/TXT STS 219 87 start date Gleevec Nov ’01 G Vs. Gem/TXT STS Jan ’03 Columbia 15 NP Emory P* Mayo 6 MD Anderson 45 20 U of Michigan 69 29 Memorial Sloan Kettering 34 11 National Cancer Institute P Partners Dana Farber Massachusetts General 1 UofCalifornia Los Angeles Washington Cancer Center 14 10 Lutheran General ** 42 Total 219 87 P=Participating NP=Not Participating *Awaiting Contract **No longer accruing

CR PR CR PR SD SD PD PD Month 2 Month 4

PRACTICAL ADVANTAGES OF THE BAYESIAN DESIGN The hierarchical model allows data from each subtype to provide information about parameters in all other subtypes It avoids two undesirable approaches, conducting : - One trial, assuming one common parameter, ignoring the subtypes, or - Separate trials that ignore each others’ data User-friendly front ends greatly facilitate trial conduct

95% Posterior Credible Intervals by Histologic Subtype q = Pr( Response )

74 yo man with myofibroblastic sarcoma Pre-Gleevec H &. E 8 weeks on Rx cKIT

65 yo man with malignant fibrous histiocytoma Pre-Gleevec H & E 2 weeks on Rx cKIT

Planned Studies Gemcitabine/docetaxel in bone sarcomas Imatinib neoaduvant treatment of DFSP AMG 706 Phase II trial in sarcoma BMS SRC inhibitor Ziopharm active ifosphamide moiety Uterine sarcoma adjuvant therapy